Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?

Luetic, Geraldine; Menichini, María Laura; Vrech, Cárlos; Pappolla, Agustín; Patrucco, Liliana; Cristiano, Edgardo; Marrodán, Mariano; Ysrraelit, María Célica; Fiol, Marcela; Correale, Jorge; Cohen, Leila; Alonso, Ricardo; Silva, Berenice; Casas, Magdalena; Garcea, Orlando; Deri, Norma; Burgos, Marcos; Liwacki, Susana; Tkachuk, Verónica; Barboza, Andrés; Piedrabuena, Raúl; Blaya, Patricio; Steinberg, Judith; Martínez, Alejandra; Carrá, Adriana; Tavolini, Darío; López, Pablo A.; Knorre, Eduardo; Nofal, Pedro; Volman, Gabriel; Contentti, Edgar Carnero; Pinheiro, Amelia Alves; Leguizamón, Felisa; Silva, Emanuel; Hryb, Javier; Balbuena, María Eugenia; Zanga, Gisela; Köhler, Manfred; Chertcoff, Aníbal; Lázaro, Luciana; Tizio, Santiago; Mainela, Carolina; Reich, Edgardo; Recchia, Luciano; Blanche, Jorge; Marcilla, Marcela Parada; Fracaro, María Eugenia; Sgrilli, Gustavo; Divi, Pablo; Jacobo, Miguel; Cabrera, Mariela; Cassará, Fátima Pagani; Sinay, Vladimiro; Curbelo, Celeste; Míguez, Jimena; Coppola, Mariano; Liguori, Nora Fernández; Martos, Iván; Pettinicchi, Juan Pablo; Viglione, Juan Pablo; José, Gustavo; Bestoso, Santiago; Manzi, Rubén; Vázquez, Gabriel; Nadur, Débora; Martínez, Carlos; Serena, Marina Alonso; Rojas, Juan Ignacio

doi:10.1016/j.msard.2021.103401

Cited by 8 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some publications regarding the impact of gender on the prognosis of MS suggest that the male gender is among the poor prognostic factors, other publications state that the impact of gender on prognosis is not significant 28,29 . In a study that included 1,074 men and 2,025 women, it was observed that there was no difference between the genders when looking at the progressive MS phenotype 30 . In our study, there was no significant difference in terms of gender between the group with EDSS below 4 and the group with EDSS 4 and above.…”

Section: Discussionmentioning

confidence: 99%

Multipl sklerozda uzun dönem yeti yitimi: 20 yıllık uzunlamasına bir çalışma

BÜNÜL

2023

Cukurova Medical Journal

View full text Add to dashboard Cite

Purpose: This study investigated the long-term clinical and demographic characteristics of multiple sclerosis (MS) patients to predict disease prognosis. Materials and Methods: Two hundred and seventy-five MS patients diagnosed using the Poser or McDonald criteria were retrospectively analyzed. They were categorized based on their Expanded Disability Status Scale (EDSS) scores: below 4 (group 1) and 4 or above (group 2). Results: The average patient age was 55.45 ± 9.63 years, with a disease duration of 26.76 ± 6.08 years. The initial EDSS scores increased from 2.56 ± 2.36 to 4.23 ± 1.8 after 20 years. Of the patients, 69.1% had EDSS scores of 4 or higher after 20 years. Notably, patients with supratentorial and spinal cord involvement at onset had higher EDSS scores. Logistic regression analysis revealed that a higher initial EDSS score, no full recovery after the first attack, and a longer duration between attacks were associated with a higher risk of an EDSS score of 4 or above. Conclusion: Thisr study shows that an increase in the initial EDSS score is predictive of long-term disability in patients with MS. Having information on long-term, real-life data in MS is highly valuable in terms of understanding the course of the disease, its monitoring, and treatment selection.

show abstract

Section: Discussionmentioning

confidence: 99%

Multipl sklerozda uzun dönem yeti yitimi: 20 yıllık uzunlamasına bir çalışma

BÜNÜL

2023

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

“…36 The prevalence of progressive cases is around 14% in Denmark 37 and Chile, 38 around 27% in Germany, 39 and 8% in Argentina. 40 The difference in the statistics could be the result of the study population and variable definitions. For example, in the German study, only + 18-year-old cases were included, or in the survey from Argentina, secondary-progressive MS (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome (CIS) cases were considered relapsing-onset versus PPMS cases as progressive-onset MS.…”

Section: Discussionmentioning

confidence: 99%

Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis

Ghadiri,

Sahraian,

Ashtari

et al. 2023

Arch Iran Med

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) may be affected by socioeconomic status (SES). This study aims to explore the determinants of SES among Iranian patients with MS and examine how these factors relate to disability and disease progression. Methods: All patients with MS listed in the nationwide MS registry of Iran (NMSRI) until January 8, 2022, were included in this population-based study. Results: Among the 5153 patients, most were female (74.5%), married (70.8%), and did not hold an academic degree (53.8%). Unemployment (OR: 3.75) and being unmarried (OR: 2.60) were significantly associated with Expanded Disability Status Scale (EDSS)≥6, and the time to progression was shorter in the unemployed group (P value: 0.03). There was also a significant negative correlation between the time to progression and the age at disease onset. Conclusion: The study suggests that providing financial and social support to MS patients and their families through investment could reduce both individual and societal burdens.

show abstract

Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis

et al. 2022

View full text Add to dashboard Cite

Background Hand dexterity impairment is a key feature of disability in people with primary progressive multiple sclerosis (PPMS). So far, ocrelizumab, a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, is the only therapy approved for PPMS and recent analysis reported its ability to reduce the risk of upper limb disability progression. However, the neural mechanisms underlying hand impairment in PPMS and the brain networks behind the effect of ocrelizumab on manual dexterity are not fully understood. Objective Main aims of our study were: (i) to investigate neurophysiological and behavioural correlates of hand function impairment in subjects with PPMS, and (ii) to use neurophysiologic and behavioural measures to track the effects of ocrelizumab therapy on manual dexterity. Methods Seventeen PPMS patients and 17 healthy-controls underwent routine neurophysiological protocols assessing the integrity of cortico-spinal and somatosensory pathways and advanced transcranial magnetic stimulation (TMS) protocols evaluating inhibitory (short and long interval intracortical inhibition, short-latency afferent inhibition) and facilitatory (motor thresholds, intracortical facilitation, short-interval intracortical facilitation) circuits in the primary motor cortex. All subjects also underwent behavioural analysis of hand dexterity by means of nine-hole peg test and finger movement analysis, and hand strength with handgrip and three-point pinch test. Neurophysiological and clinical assessments of hand functionality were also performed after 1 year of ocrelizumab therapy. Results At baseline PPMS patients displayed a significant impairment of hand dexterity and strength compared to healthy controls (all p < 0.03). Neurophysiological study disclosed prolonged latencies of standard somatosensory and motor evoked potentials (all p < 0.025) and an overall reduction of intracortical excitability at TMS protocols, involving both excitatory and inhibitory circuits. Importantly, hand dexterity impairment, indexed by delayed 9HPT, correlated with TMS protocols investigating cortical sensorimotor integration (short-latency afferent inhibition, SAI), p = 0.009. Both parameters, 9HPT (p = 0.01) and SAI (p = 0.01), displayed a significant improvement after 1 year of therapy with ocrelizumab. Conclusion Intracortical sensorimotor networks are involved in hand dexterity dysfunction of PPMS. Ocrelizumab therapy displays a beneficial effect on hand dexterity impairment most likely through intracortical networks implicated in fast sensorimotor integration.

show abstract

Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?

Cited by 8 publications

References 21 publications

Multipl sklerozda uzun dönem yeti yitimi: 20 yıllık uzunlamasına bir çalışma

Multipl sklerozda uzun dönem yeti yitimi: 20 yıllık uzunlamasına bir çalışma

Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis

Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis

Contact Info

Product

Resources

About